At Accord BioPharma, we are pleased to announce our initiative: PRO•STATE of Mind.
From getting the facts about prostate cancer, to understanding the importance of early detection, to being a part of the community, this is the place for prostate cancer education, empowerment, and support.
Our goal is to go beyond biology and improve the patient experience throughout their journey. That includes men living with prostate cancer—and their loved ones.
The prostate is a gland that surrounds the male uretha and helps produce semen, the fluid that carries sperm.
Prostate cancer is a disease that affects men, usually in middle age or later. In this disease, cells in the prostate become abnormal, multiply without control, and form a tumor.
About 1 in 7 men will be diagnosed with prostate cancer at some time during their life. More than 60 percent of prostate cancers are diagnosed after age 65, and the disorder is rare before age 40.
(Source: StoryMD.com)
Sometimes, prostate cancer symptoms can be confused with non-cancerous issues.
It’s true! An enlarged prostate is common in men over age 50—and may be causing these symptoms—without being cancerous.
That’s why it’s important to get screened. Your doctor can make sure you get the right exams and tests to understand what is causing your symptoms.
Not actual patient.
Urinary symptoms:
Sexual symptoms:
(Source: zerocancer.org)
If you have concerns about symptoms,talk to your healthcare provider
All men are at risk for prostate cancer, but there are some factors that can increase your risk.
Risk increases dramatically after age 50
Some genes have been linked to prostate cancer
Having a brother or father with the disease increases risk
Men of African descent are at a higher risk
A high-fat diet increases the chances of getting prostate cancer
High levels of testosterone can cause or accelerate the disease
(Source: StoryMD.com)
Visit StoryMD to learn more about prostate cancer Explore now
The U.S. Preventive Services Task Force recommends that men ages 55 to 69 years discuss the possible benefits and harms of prostate-specific antigen (PSA) screening with their health care provider and make an individualized decision about whether to get screened.
(Source: US Centers for Disease Control and Prevention)
Ask your healthcare provider about screening options
Get support by talking to other men who are dealing with prostate cancer. It can help you stay current on your condition and learn the best ways to take care of yourself. Advocacy groups have resources that can help you live with advanced prostate cancer.
Visit ZERO Prostate Cancer to find a group that’s right for you.
Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.
CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.
Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.
Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.
Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.
Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.
Monitor serum levels of testosterone following injection of CAMCEVI.
Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.
The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.
CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.
Click here for full Prescribing Information.
©2026 Accord BioPharma, Inc. All rights reserved WSB-ABI-2400001
